Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Recent breakthroughs in understanding the prostaglandin D2 (PGD2) receptor 1 (DP1) are paving the way for innovative ...

For patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment is not associated with an increased risk for psychiatric adverse events or worsening ...

Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society of Clinical Oncology (ASCO) Annual ...

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is ...

Muscimol, a GABA-A (GABAA) receptor agonist, enhances GABA's inhibitory effect on neuronal activity by activating GABAA ...

Here's a recap of the week’s most important stories.

Data to be presented at ASCO reflect Boehringer's broad pipeline and growing body of evidence supporting innovative therapies for various cancersPatient-reported outcomes from the Beamion LUNG-1 study ...